SAN DIEGO, Sept. 8, 2016 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NasdaqCM: MBVX), a clinical-stage oncology drug development company, today announced the Company has issued a letter to shareholders discussing recent positive events and upcoming near-term significant milestones.
Highlights of the letter include:
- Discussion of MabVax’s recent accomplishments that have met previously announced timelines for clinical and corporate development.
- The uplisting of its shares onto the Nasdaq Capital Market and equity research initiation by Laidlaw & Company
- The Company’s current status of its clinical development pipeline and updates on significant near-term milestones for MVT-5873, MVT-2163, and MVT-1075, and work on its emerging pipeline of new human antibody candidates.
- Review of the Company’s ongoing collaborations and partnering discussions that include Memorial Sloan Kettering Cancer Center, Rockefeller University and Heidelberg Pharma.
- Review of its investment focus that enables MabVax to advance its product programs towards important near-term clinical development milestones.
To read the Letter to Shareholders in full, please visit: www.mabvax.com
About MabVax
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been vaccinated against targeted cancers with the Company’s proprietary vaccines. MabVax’s HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center, or MSK. In preclinical research, the 5B1 antibody has demonstrated high specificity and affinity, and has shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancers. The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer. MabVax’s two lead antibody clinical programs, currently in Phase I clinical trials, utilize HuMab-5B1 as a naked antibody (MVT-5873) and as an immuno-PET imaging agent (MVT-2163). Additional information is available at www.mabvax.com.
Forward Looking Statements:
This press release contains “forward-looking statements” regarding matters that are not historical facts, including statements relating to the Company’s clinical trials and product development pipeline. We have no assurance that all of the product development pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled “Risk Factors” in its annual report on Form 10-K for the fiscal year ended December 31, 2015, as amended and supplemented from time to time and the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.
For further information:
MabVax Investor Relations
858-259-9405 x302
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mabvax-therapeutics-issues-letter-to-shareholders-post-uplisting-onto-the-nasdaq-capital-market-300324489.html
SOURCE MabVax Therapeutics Holdings, Inc.
